Labcorp’s pathologists will use the software to review, interpret and manage digital images of slides for primary diagnosis.

LH eyes growth via specialty test expansion, acquisitions and LaunchPad savings, but currency headwinds and macro pressures cloud the outlook.

Labcorp expanded its partnership with PathAI to offer its FDA-cleared digital pathology platform at the life science giant’s U.S. network of anatomical pathology labs and participating hospitals.

The tentative contract comes after doctors, patients and staff raises concerns over North Carolina-based Labcorp’s ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx 1, an FDA-cleared digital pathology ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

(LH) on Tuesday reported fourth-quarter profit of $164.7 million. The Burlington, North Carolina-based company said it had ...

Clemson University announced today a strategic collaboration with Labcorp, a global leader of innovative and comprehensive laboratory services, to improve healthcare access, expand educational ...

Brigade Group has leased 156,000 sq ft at Brigade Twin Towers to MANN+HUMMEL and Labcorp, signalling sustained demand for ...

Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...